Literature DB >> 20819558

Intravitreal bevacizumab injection for chronic central serous chorioretinopathy.

Xiu-juan Li1, Jin-song Zhang.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20819558

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  5 in total

Review 1.  Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.

Authors:  Y-R Chung; E J Seo; H M Lew; K H Lee
Journal:  Eye (Lond)       Date:  2013-11-08       Impact factor: 3.775

Review 2.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

3.  Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.

Authors:  G A Kim; T H Rim; S C Lee; S H Byeon; H J Koh; S S Kim; C S Lee
Journal:  Eye (Lond)       Date:  2015-05-08       Impact factor: 3.775

Review 4.  Interventions for central serous chorioretinopathy: a network meta-analysis.

Authors:  Mahsa Salehi; Adam S Wenick; Hua Andrew Law; Jennifer R Evans; Peter Gehlbach
Journal:  Cochrane Database Syst Rev       Date:  2015-12-22

5.  Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage.

Authors:  Xiu-Juan Li; Xiao-Peng Yang; Qiu-Ming Li; Yu-Ying Wang; Xiao-Bei Lyu
Journal:  Chin Med J (Engl)       Date:  2015-08-05       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.